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According to current EU monograph of the Committee on Herbal Medicinal Products of 
European Medicines Agency (EMA/HMPC) for ginkgo leaf, Ginkgonis folium (Ginkgo biloba, 
Ginkgoaceae), herbal medicines prepared from refined and quantified dry extract of ginkgo leaf 
are used for the improvement of (age-associated) cognitive impairment and of quality of life in 
mild dementia. It was demonstrated in clinical trials that long-term use of the extract is effective 
mainly in patients more than 50 years old. The precise mode of action is not known. According 
to Ph. Eur., the extract should contain 22.0-27.0% of flavonoids, 2.8-3.4% of ginkgolides A, B 
and C, and 2.6-3.2% of bilobalide, which are active constituents, and maximum 5 ppm of 
ginkgolic acids, which are potential allergens. These herbal medicines are characterized by 
corresponding posology, duration of use, contraindications, special warnings, and precautions for 
use, interactions and possible undesirable reactions. 
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The number of people suffering from dementia is rising rapidly. It affected 47 
million people in 2015 and the predictions are that this number will increase to 75 million 
in 2030 and 132 million by 2050 (1). Up until the late 1960s, it was thought that senile 
dementia is of vascular etiology (2). Today it is known that vascular dementia (VaD) is 
the second most abundant type of dementia (15-25%), after dementia in Alzheimer’s 
disease (AD), which is the most common one (60-75%) (2,3). Although pure VaD and 
AD exist, in neuropathology examinations it is often found that these two pathologies are 
mixed (3). 
Among herbal medicines, those prepared from the appropriate dried, purified 
extract of ginkgo leaf are widely used in dementia treatment since the 1990s (3). In the 
year 2015 the Committee on Herbal Medicinal Products of European Medicines Agency 
(EMA/HMPC) approved well-established use (WEU) of this ginkgo leaf extract in 
therapeutic area circulatory disorders (4), for improvement of (age-associated) cognitive 
impairment and of quality of life in mild dementia (5). 
The ginkgo tree 
The ginkgo tree, Ginkgo biloba L. (Ginkgoaceae), often referred to as „the living 
fossil”, is Tertiary relict and the sole survivor of the gymnosperm class Ginkgoatae, which 
representatives were widely distributed on Earth during Mesozoic (6-8). The term biloba 
is related to bilobed shape of the leaves (9). This tall, deciduous tree grows in wild in 
China, Japan, and Korea, but only a few localities in China represent its natural refugia 
(6,8). Ginkgo is also cultivated, both for use in pharmaceutical industry and in parks as 
ornamental tree. It is very resistant to plant diseases, as well as air pollution, and thus it 
is suitable for cultivation in urban areas (6,10). 
The ginkgo tree is a dioecious plant; female individuals produce seeds (often 
wrongly called fruits or nuts) (6,11). In Chinese traditional medicine, ginkgo seeds have 
a long history of use as a tonic and against asthma, chronic bronchitis, tuberculosis, some 
urinary and gynecological disorders, etc. They are also consumed as food (but are 
potentially toxic in larger amounts). On the other hand, only very few historical records 
(dating from the 15th and 16th century) on the traditional use of ginkgo leaves in China 
exist (dermally against freckles, and internally to treat dysentery and diarrhea) (10,12,13). 
The leaves have been introduced in the late 1970s into Chinese pharmacopoeias, for the 




Use of ginkgo leaf extract in mild dementia 
Pharmaceutical quality  
For use in the pharmaceutical industry, ginkgo leaf is mainly collected from 
plantations in China, France, and the USA; it is also cultivated in Australia, Korea, Japan 
and New Zealand (14). Cultivated ginkgo trees are pruned into bush forms, and the leaves 
are harvested with appropriate machines (13).  
Pharmaceutical quality of the herbal drug Ginkgonis folium and the corresponding 
extract is defined in European Pharmacopoeia (Ph. Eur.) monographs. Ginkgonis folium1 
is official in Ph. Eur. starting from 2002 (edition 4.0) and represents whole or fragmented, 
dried leaf of Ginkgo biloba. It should contain not less than 0.5% of flavonoids, expressed 
as flavone glycosides (determined by HPLC method). Ginkgo dry extract, refined and 
quantified, Ginkgonis extractum siccum raffinatum et quantificatum, is official in Ph. Eur. 
starting from 2008 (edition 6.1), and is produced from the herbal drug by an appropriate 
procedure using organic solvents and their mixtures with water, physical separation steps, 
as well as other suitable processes. The extract should contain 22.0-27.0% of flavonoids, 
expressed as flavone glycosides, 2.6-3.2% of bilobalide, 2.8-3.4% of ginkgolides A, B, 
and C, and maximum 5 ppm ginkgolic acids (constituents are determined by HPLC 
method) (16).  
According to EMA/HMPC EU monograph on ginkgo leaf, herbal medicinal 
products with well-established use (WEU HMPs) are prepared from the dry extract of the 
ginkgo leaf (DER 35-67:1; acetone 60%, w/w), and this extract should be in accordance 
with Ph. Eur. monograph Ginkgonis extractum siccum raffinatum et quantificatum (5). 
The composition of this extract, in general, corresponds to patented, so-called special 
extracts EGb 761 and LI 13702 (18). Extract EGb 761 was patented by German 
pharmaceutical company Dr. Willmar Schwabe, in cooperation with French 
pharmaceutical company Beaufour-IPSEN, and LI 1370 by another German 
pharmaceutical company Lichtwer Pharma (13,19). Publication of EMA/HMPC EU 
monograph has made it possible to market herbal medicines not only from EGb 761 (most 
commonly) and LI 1370 but also from other extracts that meet the quality requirements. 
Multiple purification of the extract aims to achieve high content of active principles 
and to decrease the content or remove undesirable components (13). Active principles 
include flavonoids and terpene lactones. Among flavonoids, the most common are 
glycosides of kaempferol, quercetin, and isorhamnetin, i.e. their mono-, bi- and triosides 
 
1  In the literature, Latin name Ginkgo folium is also found; however this term is not appropriate 
because in Latin name of herbal drug, the name of plant genus (in this case Ginkgo) must be in genitive 
(i.e. Ginkgonis) (15).  
2  According to previous regulations, these extracts were referred to as standardized (lat. normatum). 





(glucose, rhamnose, and glucorhamnose are usual sugar units), as well as esters of 
biosides with p-coumaric acid. The extract also contains smaller amounts of glycosides 
of apigenin and luteolin. Terpene lactones comprise diterpene trilactones: ginkgolides A, 
B, C, J and M, and sesquiterpene trilactone bilobalide (13,20).  
Undesirable components include compounds with large molecular mass: tannins 
(polymeric proanthocyanidins, PPC), polysaccharides and proteins, and compounds that 
are slightly soluble in water: biflavones, e.g. amentoflavone, bilobetin, ginkgetin, as well 
as ginkgolic acids. Ginkgolic acids represent 2-hydroxy-6-alkylbenzoic acids with 
different side alkyl chains. They are potential allergens, and because of that their 
maximum content is limited to 5 ppm (13,20).  
Besides, ginkgotoxin (4′-O-methylpyridoxine) also potentially raises safety 
concerns on the use of ginkgo leaf extract. It acts as an antivitamin of vitamin B6 (11); 
deficiency of vitamin B6 could trigger seizures in some patients with epilepsy (21). 
Because of this, corresponding precautions regarding the use of ginkgo leaf extract in 
patients with epilepsy exist (5). Ginkgotoxin is partially removed during the 
manufacturing process patented by Dr. Willmar Schwabe, i.e. EGb 761 contains less than 
200 ppm of this constituent (13). 
Clinical efficacy  
More than 60 various clinical trials testing ginkgo leaf extracts in patients diagnosed 
with some type of dementia or similar condition (first trials included patients diagnosed 
with cerebrovascular insufficiency) have been conducted since the 1970s (3,13,22). 
EMA/HMPC assessed 19 randomized, controlled and double-blind clinical trials; 
in 15 of them ginkgo leaf extract EGb 761 was tested, and nine of these (one lasted for a 
year, eight for six months) involved patients with mild to moderate dementia, including 
patients with Alzheimer disease (AD), vascular dementia (VaD) and/or mixed form of 
dementia (patients were more than 45 years old in one study, and more than 50 years old 
in other studies) (23).  
In six of nine of these studies, conclusions were positive [Herrschaft et al. (24), Ihl 
et al. (25-27), Napryeyenko et al. (28,29), Kanowski et al. (30,31), Le Bars et al. (32) and 
Yancheva et al. (33)]. In trials on patients with different types of dementia, mainly general 
conclusions (regardless of dementia type) were drawn, while in three more recent studies 
[Herrschaft et al. (24), Ihl et al. (25-27) and Napryeyenko et al. (28,29)], the effects of the 
extract were assessed in every type of dementia separately, and in all three cases 
conclusions were positive. Besides the effect on cognitive performance, in studies of 
Herrschaft et al. (24) and Ihl et al. (25-27), improvement of patients’ quality of life is also 
highlighted. Eight of nine of these trials were placebo-controlled. Only in one study (on 
patients with AD), a drug (donepezil) was used as a control; the authors hypothesized that 




donepezil”, and that combination therapy was superior compared to monotherapy, with 
fewer side effects. However, the main drawback of this study is the fact that it was 
conducted on a small number of patients with AD [Yancheva et al. (33)]. Despite having 
limited and transient efficacy, acetylcholinesterase (AChE) inhibitors (tacrine, donepezil, 
rivastigmine, and galantamine) and N-methyl-D-aspartic acid (NMDA) receptor 
antagonist memantine are the only drugs approved for treating AD (34), and further, well-
designed studies comparing the efficacy of these drugs with ginkgo leaf extract, as well 
as those investigating efficacy of their combined therapy in AD are necessary. 
In two of nine above-mentioned studies, the conclusions were negative [Van 
Dongen et al. (35) and McCarney et al. (36)]. However, in one of them, the lower daily 
dose of the extract (120 mg) was administered (36). In the remaining study [Schneider et 
al. (37)], the conclusion was not drawn. 
EMA/HMPC (23) also evaluated five meta-analyses (involving 819-4423 patients), 
two of which (on 2138 and 2372 patients) included only clinical trials testing EGb 761 
extract (all among nine above-mentioned studies) and both led to positive conclusions 
(38,39). EMA/HMPC also assessed negative Cochrane meta-analysis (22). According to 
this meta-analysis, „the evidence that ginkgo leaf extract has predictable and clinically 
significant benefit for people with dementia or cognitive impairment is inconsistent and 
unreliable”, due to unsatisfactory design of the most of the assessed trials (different 
extracts, doses, duration of treatment, a small number of patients, etc.). Cochrane meta-
analysis comprised much larger number (i.e. 36) of clinical trials, compared to two 
discussed above (nine and six), thus it was less restrictive, and also recent, affirmative 
studies [Herrschaft et al. (24) and Ihl et al. (25-27)] were not available to the authors. 
Based on all these facts, EMA/HMPC concluded that the extract in a daily dose of 
240 mg fulfills criteria (i.e. there is enough clinical evidence) for well-established use 
herbal medicinal product (WEU HMP); long term administration of the extract resulted 
in improvement of cognitive performance in older patients, especially in those of 50 years 
and above (the most relevant clinical trials were performed in subjects aged 50 and older) 
(23). 
This EMA/HMPC indication differs from those given in older monographs on 
ginkgo leaf, earlier published by Commission E of German Federal Institute for Drugs 
and Medical Devices (40), World Health Organization, WHO (41) and European 
Scientific Cooperative On Phytotherapy, ESCOP (42). While in older monographs types 
of dementia are stated (i.e. symptomatic treatment of dementia syndromes, including 
primary degenerative dementia, vascular dementia, and mixed forms of both), in 
EMA/HMPC EU monograph this is no longer the case. 
Among 15 previously mentioned clinical trials dealing with EGb 761 (assessed by 
EMA/HMPC), in two large, long-term, multicenter, randomized, double-blind and 




more than 75 years old, and Vellas et al. (44), lasted for 5 years on 2854 patients more 
than 70 years old], the potential of the extract to prevent dementia was investigated. In 
both studies, it was concluded that the extract was „not effective in reducing either the 
overall incidence rate of dementia or AD incidence in elderly individuals with normal 
cognition or those with mild cognitive impairment (MCI)” (23). The recommendation in 
National guideline for AD of the Republic of Serbia (45) is based on the results of these 
two trials, as well as on the additional analysis of the results of DeKosky et al. (43), 
performed by Snitz et al. (46), in which it was concluded that the use of the extract „did 
not result in less cognitive decline in adults (aged 75 and older) with normal cognition or 
with MCI” (45). 
Similarly to our National guideline for AD, according to German guideline for 
dementia, EGb 761 is not recommended for the prevention of dementia (47). In both 
German guideline for dementia and German guideline for vascular dementia, it is 
additionally stated, based on newer evidence on clinical efficacy [Herrschaft et al. (24) 
and Ihl et al. (26,27)], that EGb 761 in a daily dose of 240 mg can be considered in 
dementia treatment (47,48). 
In a recent meta-analysis, performed by Savaskan et al. (49) (after the publication 
of EMA/HMPC Assessment report and EU Monograph on ginkgo leaf), the effect of EGb 
761 on neuropsychiatric symptoms in patients with dementia was evaluated. This meta-
analysis comprised four randomized, placebo-controlled, double-blind clinical trials 
involving the total of 1628 patients [Herrschaft et al. (24), Ihl et al. (26), Napryeyenko et 
al. (28) and Nikolova et al. (50)] and drawn conclusion that the extract improves 
behavioral and psychological symptoms (except psychotic-like features) in patients 
suffering from AD and from VaD when it was given for 22-24 weeks in a daily dose of 
240 mg. 
It is important to note that other indications included in older monographs on ginkgo 
leaf (Commission E, WHO, ESCOP), i.e. neurosensory disorders: vertigo and tinnitus, as 
well as peripheral arterial occlusive disease (PAOD) in stage II according to Fontaine 
(intermittent claudication) (40-42), were not listed in EMA/HMPC EU monograph. 
Namely, subsequent analysis of clinical trials on patients with vertigo, tinnitus, and 
PAOD, as well as evaluation of newer trials on patients with tinnitus and PAOD showed 
that there is not enough clinical evidence on efficacy for these indications (23). However, 
in a recent meta-analysis (51) of five clinical trials (on a total of 2111 subjects) 
[Herrschaft et al. (24), Ihl et al. (26), Napryeyenko et al. (28), Schneider et al. (37) and 
Nikolova et al. (50)], on patients with dementia suffering at the same time from vertigo 
and tinnitus, it is concluded that EGb 761 in a daily dose of 240 mg alleviates these 




Pharmacological effects  
The exact mode of action of ginkgo leaf extract in mild dementia is not known. 
Increased vigilance (measured in EEG test) in geriatric patients (60 subjects, 57-77 years 
old) with age-related mental deterioration was observed (52). 
Most pharmacological studies demonstrated its effects on cerebral (as well as 
peripheral) circulation. Human pharmacological data show a decrease in blood viscosity 
and improvement of cerebral perfusion in specific areas in healthy male volunteers (48 
patients, 60-70 years old) (53), reduction in platelet aggregation (ex vivo) (54) and 
vasodilation of forearm blood vessels causing increased regional blood flow in healthy 
subjects (16 patients, 21-47 years old) (55). A study in mice demonstrated that the extract 
and its flavonoid-free fraction prolonged the survival time under lethal hypoxia (56). In 
another study in mice, bilobalide and ginkgolides A and B significantly reduced the 
infarct size after occlusion of the middle cerebral artery (57). Accordingly, in vitro and in 
vivo (in rats) experiments showed that the extract and bilobalide improved mitochondrial 
function, attenuating the hypoxia-induced ATP decrease (13,58). The protective effect of 
the extract and bilobalide on brain edema in rats was also demonstrated (13). Also, the 
extract protected tissues (both brain and myocardium) from ischemia/reperfusion 
damages (showed in vivo in rats and in vitro) (59). In a search for mechanisms underlying 
these pharmacological effects, in vitro studies using rabbit platelets (60,61) and human 
platelets (62), showed that ginkgolides A, B, and C inhibit platelet-activating factor 
(PAF). Furthermore, in vitro experiments on human endothelial cells, isolated rat aortic 
rings, as well as in vivo experiments in rats demonstrated that the extract promotes 
endothelial NO release (13,63).  
Other studies showed antioxidant and anti-inflammatory activities of the extract and 
its constituents. Radical scavenging potential of ginkgo flavonoids, as well as the ability 
of the extract to increase levels of antioxidant enzymes (such as superoxide dismutase, 
glutathione peroxidase, and catalase), were demonstrated in vivo and/or in vitro (64). An 
in vitro study showed that ginkgolides A and B inhibited TNF-α and IL-1 (65); inhibition 
of PAF, which also has pro-inflammatory properties, contributes to anti-inflammatory 
activity (64). 
Antioxidant and anti-inflammatory activity and protective effects in hypoxia 
contribute to the neuroprotective potential of ginkgo leaf extract. Additionally, other 
effects that can contribute to neuroprotection were also shown: anti-apoptotic effect (in 
vitro for the extract, ginkgolides B and J, bilobalide and quercetin), protective effects 
against amyloidogenesis (for the extract in vitro and in vivo in mice) and amyloid-β 
aggregation (in vitro for the extract, ginkgolide J, bilobalide and flavonoid fraction), 





Effects on neurotransmission were also observed in some in vitro and in vivo studies 
(13). Chronic oral treatment with the extract led to the increase of muscarinic receptors 
number and cholinergic transmission in the hippocampus of aged rats (66). The extract 
and its two specific quercetin and kaempferol biosides esters with p-coumaric acid 
(together they comprise about 4.5% of EGb 761) increased dopamine and acetylcholine 
levels in the rat medial prefrontal cortex after oral administration (the effect was not 
observed with aglycone isorhamnetin) (67).  
Well-established use herbal medicinal products (WEU HMPs) from 
ginkgo leaf extract in mild dementia 
Posology and duration of use 
WEU HMPs from the refined and quantified dry extract of ginkgo leaf are prepared 
in liquid or solid dosage forms for oral use. In adults and elderly, a single dose is 120-240 
mg and a daily dose is 240 mg. For children and adolescents, no relevant indication exists. 
Treatment should last for at least eight weeks, and after three months, if there is no 
improvement of symptoms or if they intensify, a doctor should evaluate the justifiability 
of continuation of the treatment (5).  
Contraindications, special warnings, and precautions for use 
WEU HMPs from ginkgo leaf extract are contraindicated in the case of 
hypersensitivity to the active substance or pregnancy. 
They can be used only after consultation with a doctor in patients with a 
pathologically increased bleeding tendency (hemorrhagic diathesis) and those taking 
anticoagulants and antiplatelet drugs. As a precaution, these HMPs should be 
discontinued three to four days before surgery, since they might increase susceptibility to 
bleeding (5). These precautions are based on the fact that ginkgo leaf extract affects 
platelet aggregation (23,54).  
In patients suffering from epilepsy, further seizures induced by the use of ginkgo 
leaf extract cannot be excluded (5). This precaution is introduced because the recurrence 
of well-controlled epilepsy after administration of ginkgo leaf extract was reported by 
two elderly patients. However, it was not specified exactly which ginkgo leaf extracts 
were taken in these cases (68). It is already mentioned that convulsions could be attributed 
to ginkgotoxin and that during the manufacturing process of EGb 761, the content of 
ginkgotoxin is lowered to maximally 200 ppm, which means that administration of a daily 
dose of the extract (240 mg) results in the intake of approximately 48 µg of ginkgotoxin. 
On the other hand, the seeds contain a much higher quantity of ginkgotoxin, i.e. up to 85 
µg/raw seed. Thus, the risk of convulsions is much higher after the consumption of seeds. 
For example, in children convulsions were observed after consuming 15-60 raw seeds 





Ginkgo leaf extract may potentiate the effect of anticoagulants (e.g. warfarin and 
dabigatran) or antiplatelet drugs (e.g. acetylsalicylic acid and clopidogrel) (5) because 
ginkgolides inhibit PAF (60-62). In addition, possible potentiation of the effect of 
dabigatran (formulated as prodrug dabigatran etexilate, which is a substrate for intestinal 
P-glycoprotein) (69) is suggested based on two studies on 10 and 12 healthy male 
volunteers, which indicated that ginkgo leaf extract may inhibit intestinal P-glycoprotein 
(70,71).  
In one study, the interaction of ginkgo leaf extract with nifedipine was investigated 
in eight healthy volunteers, and in two of them, maximum serum concentrations of 
nifedipine were doubled. These two subjects experienced dizziness and increased severity 
of hot flushes (5,23,72). 
The use of ginkgo leaf extract with efavirenz is not recommended because serum 
levels of efavirenz may be decreased due to CYP3A4 induction (5,23,73). 
Pregnancy and lactation 
The use of ginkgo leaf extract is contraindicated in pregnancy, mainly because it 
may increase the tendency for bleeding. There are no sufficient animal studies regarding 
reproductive toxicity, and published data are contradictory (5). For example, a study in 
mice showed that EGb 761 affected fertility and reproductive performance, caused 
vaginal bleeding, and reduced fetal viability (23,74), while a study in rats and rabbits did 
not show similar effects (23,75). 
The effects of some ginkgo leaf extract components were also tested. It was shown 
that ginkgolide B reduced the rate of maturation of oocytes, fertilization, and fetal 
development in vitro and in vivo in mice (23,76). Both ginkgolides A and B, in vitro led 
to apoptosis, decreased cell numbers, retarded early postimplantation development, and 
increased early-stage death of mouse blastocysts (23,77). High toxic potential on chick 
embryos was found for fractions rich in ginkgolic acids (23,78), but their content in 
ginkgo leaf purified extract is limited to a maximum 5 ppm (16).  
Because of insufficient data, it is not recommended to use the extract during 
lactation (5). 
Undesirable effects 
In several clinical trials and meta-analyses, it is concluded that the use of ginkgo 
leaf extract is safe (3,22,79-81). Among spontaneously reported undesirable effects, 
headache is reported as very common, and dizziness and gastrointestinal disorders (such 
as diarrhoea, abdominal pain, nausea, and vomiting) as common. Hypersensitivity 
reactions, including allergic skin reactions and other skin and subcutaneous tissue 




cerebral and gastrointestinal hemorrhage of unknown frequency) were reported after 
longtime treatment, but details on ginkgo leaf extracts taken are not specified. However, 
in clinical studies with EGb 761, such adverse effects have not been reported (3,22,23,79-
81). Moreover, based on concentrations of ginkgolides A, B and C that inhibited PAF in 
vitro and their serum levels after oral intake of the extract in a daily dose, Koch (62) 
expressed his doubts that ginkgolides could be responsible for potential hemorrhage in 
patients taking EGb 761 (62). 
EMA/HMPC concluded that overall, ginkgo leaf preparations have a reasonable 
safety profile (23). 
Traditional herbal medicinal products (THMPs) from dried ginkgo leaf 
in peripheral circulatory disorders 
As it is already stated, for WEU HMPs from ginkgo leaf extract, EMA/HMPC did 
not approve an indication peripheral arterial occlusive disease (23). On the other hand, 
EMA/HMPC approved traditional use of dried powdered leaf of ginkgo for the relief of 
the sensation of cold hands and feet, as well as the heaviness of legs associated with minor 
circulatory disorders, after serious conditions have been excluded by a doctor (5). The 
sensation of cold hands and feet and heaviness of legs refer to disorders of peripheral 
arterial and venous circulation, respectively (82,83).  
THMPs are prepared in solid dosage forms for oral use. For adults and elderly, a 
single dose is 250-360 mg, and a daily dose is 750 mg of the dried powdered ginkgo leaf. 
In the absence of adequate data, for children and adolescents under 18 years the use of 
these THMPs is not recommended. In the case that the symptoms exist for more than two 
weeks, the advice of a doctor or a qualified health care practitioner should be sought. The 
use is contraindicated in the case of hypersensitivity to the active substance. THMPs may 
enhance the effects of anticoagulants. Because of insufficient data, it is not recommended 
to use these THMPs during lactation. Regarding undesirable effects, gastrointestinal 
disorders, headaches, and allergic reactions of unknown frequency were reported (5). 
Corresponding differences in contraindications, special warnings, precautions for 
use and undesirable effects of THMPs compared to WEU HMPs can be explained by the 
fact that WEU HMPs are prepared from highly concentrated ginkgo leaf extract, 
containing much higher amounts of ingredients. 
Conclusion 
According to current EU monograph of EMA/HMPC for ginkgo leaf, well-
established use herbal medicinal products (WEU HMPs) prepared from refined and 
quantified dry extract of ginkgo leaf, Ginkgonis extractum siccum raffinatum et 
quantificatum, are used for the improvement of cognitive impairment associated with age 




weeks. EMA/HMPC defined the indication and posology based on the evaluation of 
corresponding recent clinical studies and meta-analyses, and it should be noted that they 
differ significantly from those reported in older monographs which refer to efficacy and 
safety of ginkgo leaf extract.  
It should be noted that WEU HMPs from ginkgo leaf extract are among the most 
accessible HMPs in Europe. For example, in the different countries of the European 
Union, by 31. December 2016, there was a total of 111 approved marketing authorizations 
(MA) for WEU HMPs from ginkgo leaf extract (this is the second largest number of 
approved MA for any of WEU HMPs) (84). In the Republic of Serbia currently, four 
WEU HMPs from ginkgo leaf extract are authorized (all four are in accordance with the 
EMA/HMPC EU monograph) (85). Finally, considering the no prescription required 
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Prema aktuelnoj monografiji EU Komiteta za biljne lekovite proizvode Evropske agencije 
za lekove (EMA/HMPC) za list ginka, Ginkgonis folium (Ginkgo biloba, Ginkgoaceae), biljni 
lekovi na bazi suvog prečišćenog kvantifikovanog ekstrakta lista ginka koriste se za ublažavanje 
(sa starošću povezanog) kognitivnog oštećenja i za poboljšanje kvaliteta života kod blage 
demencije. U kliničkim studijama je pokazana efikasnost hronične primene ekstrakta 
prevashodno kod pacijenata starosti preko 50 godina. Precizan mehanizam delovanja nije poznat. 
Prema Ph. Eur., ekstrakt treba da sadrži 22,0-27,0% flavonoida, 2,8-3,4% ginkolida A, B i C i 
2,6-3,2% bilobalida, koji spadaju u aktivne sastojke, kao i najviše 5 ppm ginkolnih kiselina koje 
su potencijalni alergeni. Ove biljne lekove karakterišu odgovarajući režim doziranja i dužina 
primene, kontraindikacije, posebna upozorenja i mere opreza, interakcije i moguće neželjene 
reakcije. 
 
Ključne reči: Ginkgo biloba; ekstrakt lista; blaga demencija; biljni lekovi;  
  efikasnost i bezbednost 
 
